Pharma, Clinical Research Execs Convicted for Deceiving Investors

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Biopharma, Clinical Research Executives Convicted on Charges Related to Scheme To Deceive Investors

Dennis Tosh

December 11, 2024 at 05:37 PM EST

The president and CEO of a biotechnology company and the founder and CEO of a clinical research organization have been convicted following a 20-day jury trial on charges related to an alleged scheme to deceive investors in the biotech firm (United States v. Pourhassan, No. 8:22-cr-00440-PX (D. Md.)). According to the Department of Justice (DOJ), Nader Pourhassan, the presiden... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Biopharma, Clinical Research Executives Convicted on Charges Related to Scheme To Deceive Investors

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT